While the industry obsesses over faster chips and bigger context windows, AlixPartners consultant Kevin Madura argues the real disruption ...

In an era where AI models can be as creative as they are deceptive, Vals AI founder Rayan Krishnan argues that a company's evaluation framework is ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

We celebrate 60 years of Mountain Gazette with their editor Mike Rogge. Plus: Josh Riedel on his latest project, Thirty Cabins: Stories and Hywel Mills from The Signal. We speak with Grace O’Neill and ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals Inc insiders reported 3 transactions totaling $430,930.56. Activity included 2 tax payments ($333,430.56) and 1 sale ($97,500.00) in August 2026. View more Major Holders ...